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Qual vaghezza di lauro, qual di mirto? 
Povera et nuda vai philosophia, 
dice la turba al vil guadagno intesa. 
 
Such desire for laurel, and for myrtle? 
'Poor and naked goes philosophy', 
say the crowd intent on base profit. 
 
Francesco Petrarca, Il Canzoniere (Canto 7 vv. 9-11) 
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INTRODUCTION 
 
Immune responses within the central nervous system  
The Central Nervous System (CNS) has traditionally been considered as an immunologically 
privileged site in which the immune surveillance is lacking and where the development of an 
immune response is more limited compared to other non-CNS organs. This view was based on the 
results obtained in earlier transplantation studies demonstrating that a relative tolerance to grafts is 
present in the brain and on the following complementary observations (Medawar 1948; Beckmann 
2005; Carson et al, 2006):  
1) the existence of a blood-brain barrier (BBB), a mechanical diffusion barrier for hydrophilic 
molecules, immune cells and mediators which is formed by specialized endothelial cells with tight 
junctions located at the level of brain capillaries and by the surrounding basement membrane and 
astroglial end-feet (glia limitans);  
2) the absence of a lymphatic drainage of the brain parenchyma;  
3) the lack of a constitutive expression of Major Histocompatibility Complex (MHC) class I and 
class II antigens on neural cells;  
4) no occurrence of professional antigen presenting cells (APCs) in the CNS.  
However, a growing body of evidence coming from experimental and human investigations now 
suggests that this paradigm should be modified. 
 
CNS as an immunologically specialized site 
The immune privilege of the CNS has recently been challenged by several findings showing that:  
1) rejection of tissue grafts (Mason et al, 1986) can be observed in the CNS;  
2) activated lymphocytes are able to enter the brain trafficking across the BBB in the non-inflamed 
CNS (Hickey et al, 1991);  
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3) brain antigens are efficiently drained into cervical lymph nodes via the cribroid plate and 
perineural sheaths of cranial nerves (Kida et al, 1993);  
4) CNS-associated cells acting as APCs are detectable (McMenamin, 1999);  
5) all brain cell types can express MHC class I and II molecules after activation in the inflamed 
CNS (Hemmer et al, 2004).  
In particular, it has been documented that foreign tissue grafts are rejected when injected into the 
ventricular system, whereas bystander demyelination and axonal loss are triggered by a delayed 
type hypersensitivity response after intraventricular bacterial injection (Galea et al, 2007). In 
addition, migration of activated T cells from the intravascular compartment into the CNS can occur 
by using different routes of entry (Ransohoff et al, 2003):  
a) from blood to cerebrospinal fluid (CSF) across the choroid plexus;  
b) from blood to subarachnoid space;  
c) from blood to parenchyma.  
In this setting, it is important to note that, in absence of ongoing CNS inflammation, only activated 
T cells travel into the brain since resting T lymphocytes fail to transit across the BBB. On the other 
hand, the subarachnoid and perivascular spaces of the nasal-olfactory artery are connected, via the 
cribriform plate, with nasal lymphatics and cervical lymph nodes, thus allowing CSF drainage into 
the cervical lymphatics (Ransohoff et al, 2003; Galea et al, 2007). In this way, after their migration 
in CSF from white matter through the ependyma and from grey matter along perivascular spaces, 
brain soluble proteins can be transported to local peripheral lymph nodes where they can trigger 
priming and activation of naïve T lymphocytes. Nevertheless, these interactions require local APCs 
capable of expressing specific antigens associated to MHC molecules on cell surface after 
engulfment. Resident APCs of the CNS include a variety of myeloid-lineage cells such as 
perivascular cells (macrophages), meningeal macrophages and dendritic cells, intraventricular 
macrophages and choroid plexus macrophages and dendritic cells (Ransohoff et al, 2003). 
Moreover, also microglial cells acquire APC properties in the course of CNS inflammation (Aloisi 
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et al, 2000). In this regard, of relevance is the presence of meningeal and choroid plexus dendritic 
cells which are the most effective APCs for initiating T cell responses. In fact, these cells could 
capture CSF soluble proteins coming from brain parenchyma and transport them to draining 
cervical lymph nodes. Furthermore, dendritic cells may present such antigens to naïve T cells at the 
level of local lymph nodes (Galea et al, 2007). In normal brain, a constitutive expression of MHC 
antigens is present on endothelial cells, perivascular, meningeal and choroid plexus macrophages 
and some microglial cells for MHC class I molecules (Hoftberger et al, 2004). Conversely, MHC 
class II molecules result constitutively expressed only on perivascular, meningeal and choroid 
plexus cells since their expression on resting microglia still remains a controversial issue (Aloisi et 
al, 2000; Hemmer et al., 2004). During intrathecal inflammatory responses, microglial cells and 
astrocytes become MHC-I and MHC-II positive, whereas oligodendrocytes and neurons upregulate 
MHC class I molecules (Aloisi, 2001). However, in absence of pathologic conditions, the 
interactions between the immune system and the CNS occur within the CSF, whereas brain 
parenchyma maintains a relative immune privilege. For this reason, the immune specialization of 
the CNS should be assumed to be a dynamic process regulated by functional characteristics of the 
intrathecal compartment (Galea et al, 2007). 
 
Immune surveillance in the CNS 
Under physiologic circumstances, it is widely accepted that immune surveillance is performed at the 
level of perivascular spaces (Ransohoff et al, 2003; Becher et al, 2006). In fact, the intrathecal 
compartment is constantly patrolled by T cells which have already been activated by the primary 
encounter with neural antigens in cervical lymph nodes. These cells penetrate the CSF across the 
choroid plexus and, to a lesser extent, the vessel wall of postcapillary venules located in Virchow-
Robin spaces and then accumulate principally in the perivascular spaces where they interact with 
the corresponding local APCs. At this point, if perivascular cells do not present the cognate antigen 
to T lymphocytes, these activated immunocompetent cells do not progress across the glia limitans 
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and recirculate into the blood stream or undergo apoptotic death. On the contrary, if T cells 
recognize the related antigen presented by perivascular macrophages, they cross the glia limitans, 
invade the CNS parenchyma and promote the activation of microglial cells which release several 
soluble factors leading to the development of an inflammatory response. In both these cases, the 
mechanisms of lymphocyte recruitment are largely unknown, although it has been hypothesized that 
the egress of T cells into the CSF is regulated by chemokines and adhesion molecules such as 
selectins (Rebenko-Moll et al, 2006), whereas the migration of T cells into the brain could be due to 
proteolytic enzymatic activity of matrix metalloproteinases (MMPs) (Bechmann et al, 2007). Of 
relevance, not only T cells, but also B cells can contribute to CNS immune surveillance since their 
entry into the CSF has been described (Uccelli et al, 2005). The presence of immune mechanisms 
which provide a continuous monitoring of CNS microenvironment plays a fundamental role in 
protecting the brain. In fact, immune responses contribute to host defense against pathogens and 
preservation of tissue homeostasis since they aim to eliminate of dangerous infectious agents 
invading the CNS, remove irreversible damaged cells and their products and promote tissue repair 
(Becher et al, 2006). Moreover, immune reactions to foreign antigens are self-limited because, after 
the eradication of the antigens, the immune system returns to its basal resting state due to apoptotic 
deletion of activated T cells (Jiang and Chess, 2006).  However, when the antigen is difficult to 
clear from the CNS or a self brain protein is recognized as non-self, there is a persistent antigenic 
stimulation of the immune system which favours the development of a chronic intrathecal 
inflammatory response leading to tissue destruction. Thus, immune surveillance can exert not only 
beneficial but also detrimental effects (Becher et al, 2006). Therefore, in the course of CNS immune 
surveillance, two distinct phases can be identified (Bechmann et al, 2007). The first step implies the 
migration of activated T cells from blood to perivascular spaces through choroid plexus and 
postcapillary vessels which is not necessarily associated to pathological conditions involving the 
brain since it can occur when the appearance of a strong immune response in the body promotes the 
priming of T cells at the level of the secondary lymphoid organs (Hickey, 2001). The second step is 
  9 
characterized by the penetration of activated T cells from perivascular spaces to brain parenchyma 
across the glia limitans which is a restricted phenomenon because it depends on antigen 
presentation performed by perivascular cells. In fact, activated T are able to invade the CNS only 
when they re-encounter their cognate antigen in the context of appropriate MHC molecules 
associated to perivascular APCs. Table 1 summarizes the mechanisms of CNS immune 
surveillance. 
 
Tabel 1. The biphasis nature of immune surveillance in the CNS (modified from Fainardi and 
Catellazzi, 2010). 
Phases Location Mechanisms 
Migration of activated T cells 
from blood to perivascular 
spaces (step 1) 
Choroid plexus and 
postcapillary vessell wall 
Activation of T cells in the  
secondary lymphoid organs due 
to a strong immune response in 
the body 
Migration of activated T cells 
from perivascular spaces to 
brain parenchyma (step 2) 
Glia limitans 
(astroglial end-feet) 
Recognition of cognate 
antigens by activated T cells 
after presentation in the context 
of appropriate MHC molecules 
expressed on perivascular cells 
 
Immune sentinels of the CNS 
Given their ability to act as resident APCs for T cells in normal brain, perivascular cells can be 
viewed as sentinels at the gate of the CNS parenchyma (Becher et al, 2006).  
Considering their importance in CNS immune surveillance, perivascular cells and the other resident 
APCs are persistently repopulated by bone-marrow-derived monocytes (Becher et al, 2006). 
Although this peculiarity is absent in microglial cells and astrocytes, during intrathecal 
inflammation these cells may exert APC functions and can, therefore, be considered as sentinels 
within the CNS parenchyma (Aloisi et al, 2000; Aloisi, 2001; Becher et al, 2006).  
In the inflamed CNS, there is an activation of microglial cells which upregulate MHC class I and 
class II molecules and co-stimulatory molecules at their cell surface and then acquire the ability to 
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present antigen to previously primed CD8+ and CD4+ T lymphocytes. Therefore, like meningeal 
and choroid plexus dendritic cells and perivascular cells, also microglial cells are resident APCs. 
However, while dendritic cells are professional APCs which are able to initiate a primary immune 
response by the presentation of brain antigens to naïve T cells in the secondary lymphoid organs, 
perivascular and microglial cells are non-professional APCs which trigger a secondary immune 
reaction by the presentation of neural antigens to already activated T cells in the Virchow-Robin 
space and within the brain, respectively (Aloisiet al, 2000; Aloisi, 2001; Becher et al, 2006). 
Astrocytes are cells of neuroectodermal origin which are fundamental for brain homeostasis and 
neuronal function since they contribute to the induction and maintenance of BBB by their foot 
processes, induce scar formation and tissue repair by astrogliosis, produce neurotrophic factors and 
regulate neuronal functions by providing metabolic support and uptake of neurotransmitters (Dong 
and Benveniste, 2001). During inflammation, astroglia become MHC class I-positive and can 
express low levels of MHC class II and co-stimulatory molecules (Aloisi et al, 2000; Dong and 
Benveniste, 2001; Hemmer et al, 2004; Becher et al, 2006). Therefore, the effective involvement of 
these cells in intrathecal antigen presentation still remains uncertain and, at present, is believed to 
be restricted to CD4+ T helper with Th2 phenotype (Aloisi et al, 2000). On the other hand, the 
activation of microglia and astrocytes due to the presence of an inflammatory response within the 
brain is associated to increased cellular expression of pattern-recognition receptors (PRPs) which 
can identify a broad spectrum of microbial proteins and pathogenic insults (Farina et al, 2007). In 
addition, microglial cells and astroglia share with neurons and endothelial cells the ability to 
eliminate T cells invading the CNS through Fas (CD95)/Fas ligand (FasL or CD95L)-dependent 
apoptosis under both physiologic and pathologic circumstances (Bechmann et al, 1999). The 
interaction between FasL expressed by resident brain cells and Fas expressed by immune cells 
trafficking across the BBB can induce apoptotic deletion of T cells migrating into the CNS. 
Consequently, microglia, astroglia, neurons and endothelial cells form an immunological brain 
barrier that preserves the brain against the infiltration of immunocompetent cells by the 
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maintenance of a state of immune suppression within the CNS (Bechmann et al, 1999). The 
characteristics of CNS immune sentinels are reported in Table 2.  
 
Table 2. Features of the CNS cells acting as immune sentinels in the normal and inflamed brain 
(modified from Fainardi and Castellazzi, 2010) 
Cell type Functions Mechanisms 
CNS-associated cells 
(meningeal and choroid plexus 
macrophages and dendritic 
cells, perivascular cells) 
Immune sentinels at the gate 
of the CNS parenchyma 
Expression of MHC class I and 
II antigens, co-stimulatory 
molecules and pattern-
recognition receptors  
Microglia 
 
Immune sentinels within the 
CNS parenchyma 
Expression of MHC class I and 
II antigens, co-stimulatory 
molecules, pattern-recognition 
receptors and, along with 
neurons and endothelial cells, 
Fas ligand  
Astroglia 
 
Immune sentinels within the 
CNS parenchyma 
 
Expression of MHC class I and 
II antigens, co-stimulatory 
molecules at low levels, 
pattern-recognition receptors 
and, along with neurons and 
endothelial cells, Fas ligand 
 
Role of B-cells 
CD4+ Th1 cells help the differentiation of B cells into plasma cells which produce opsonizing and 
complement-binding IgG1 and IgG3 (Hemmer et al, 2004). These antibodies cause demyelination 
via opsonisation, consisting in the stimulation of macrophage-mediated phagocytosis by binding to 
Fc receptors expressed on the surface of phagocytes, and complement activation, in which they act 
as chemoattractants for lymphocytes and macrophages. In addition, antibodies are myelinotoxic 
also by means of antibody-dependent cell-mediated cytotoxicity (ADCC) exerted by NK cells, due 
to interactions between antibodies and Fc receptors expressed on NK cells, and by the production of 
proteolytic enzymes such as MMPs (Archelos et al, 2000; Archelos and Hartung, 2000). The 
intense release of antibodies restricted to the CNS by B cells confined within the brain is referred to 
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as intrathecal IgG synthesis which is a hallmark of multiple sclerosis (MS) since such antibodies 
can be identified in the CSF of MS patients as oligoclonal bands (Correale and Bassani-Molinas, 
2002). Of note, in this phase of the CNS inflammatory response, activate astrocytes also contribute 
to intrathecal production of antibodies by the secretion of B-cell activating factor of the TNF family 
(BAFF) that is an important survival factor during B-cell maturation (Farina et al, 2007). The 
intrathecal release of antibodies is further facilitated by the development of ectopic lymphoid 
follicles in the inflamed meninges, a phenomenon indicated as lymphoid neogenesis or tertiary 
lymphoid organ formation (Uccelli et al., 2005). During CNS inflammation, the persistent antigen 
stimulation leads to a continual activation of B cells infiltrating the CNS which increase their 
expression of cytokines, such as linfotoxin-α1β2, and homeostatic chemokines, migrate into and 
colonize the meningeal layers where these activated B cells organize themselves forming ectopic 
lymphoid tissue, undergo the same recapitulation occurring in the secondary lymphoid organ and 
differentiate into memory B cells and plasma cells. The evidence of  an accumulation of memory B 
cells and short-lived plasma cells in the CSF during neuroinflammation seems to corroborate the 
assumption that B cells play a significant role as effector cells of immune responses taking place in 
inflamed brain (Cepok et al, 2005; Cepok et al, 2006).  
 
Multiple Sclerosis 
Multiple sclerosis (MS) is currently postulated to be an autoimmune chronic inflammatory disease 
of the CNS of unclear etiology in which both demyelination and axonal loss occur (Sospedra and 
Martin, 2005; Hauser and Oksenberg, 2006). Worldwide distribution of MS is reported in Figure 1. 
The disease is more common among people in Europe, the United States, Canada, New Zealand, 
and sections of Australia and less common among people in Asia and the tropics.  
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Figure 1. Worldwide distribution of MS (http://multiplesclerosis.net/what-is-ms/statistics/).  
 
MS commonly affects young adults and women more frequently than men and is clinically 
characterized by the dissemination in space and time of relapses, also called clinical attacks or 
exacerbations, which consist in the occurrence of neurological symptoms and signs (Figure 2). In 
fact, in MS, relapses typically affect different CNS functional systems (dissemination in space) in 
different periods of time separated by phases of recovery and remission (dissemination in time) 
(Compston and Coles, 2002). Clinical expression of the disease is highly variable, but three main 
courses of MS are generally recognized (Noseworthy et al, 2000; Compston and Coles, 2002). 
About 80% of MS patients begin with an initial relapsing-remitting (RR) course characterized by 
self-limited acute exacerbations followed by periods of clinical stability which, in many patients, 
evolves into a secondary-progressive (SP) phase characterized by a steady worsening in 
neurological function unrelated to acute attacks. Less often (20%), a primary progressive (PP) form 
with a slow and inexorable deterioration of clinical condition without acute attacks represents the 
onset of the disease.  
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Figure 2. MS signs and symptoms: autonomic, visual, motor, and sensory problems are the most 
common. 
(http://upload.wikimedia.org/wikipedia/commons/a/a3/Symptoms_of_multiple_sclerosis.png) 
 
However, according to the recently proposed criteria (McDonald et al, 2001; Polman et al, 2011) 
the diagnosis of MS requires additional radiological and laboratory findings. In particular, more 
than 95% of MS patients show multi-focal lesions in the periventricular white matter on T2-
weighted Magnetic Resonance Imaging (MRI) scans with or without Gadolinium (Gd) 
enhancement on T1-weighted MRI scans (Figure 3, panel A and B), which are able to demonstrate 
dissemination in space and time. On the other hand, in more than 90% of cases isoelectric focusing 
(IEF) identifies oligoclonal IgG bands only in CSF and not in the corresponding serum reflecting an 
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intrathecal synthesis of IgG sustained by few clones of antibody-secreting B cells sequestrated into 
the CNS (Figure 3, panel C). 
 
Figure 3. Magnetic Resonance Imaging (MRI) appearance of multiple sclerosis (MS) brain lesions 
disseminating the periventricular white matter as hyperintense foci on T2-weighted Fluid 
Attenuated Inversion Recovery (FLAIR) scans (panel A) and as Gadolinium (Gd)-enhanced small 
areas on post-contrast T1-weighted images (panel B). Panel C shows oligoclonal IgG bands (OCB) 
only in CSF and not in the corresponding serum reflecting an intrathecal synthesis of IgG as 
detected by isoelectric focusing (IEF) (modified from Fainardi and Castellazzi, 2010). 
 
Clinical dissemination in space is defined as the occurrence of neurological symptoms and signs 
(relapses) involving different CNS functional systems. Clinical dissemination in time is considered 
as the appearance of neurological symptoms and signs (relapses) in different periods of time 
separated by phases of recovery and remission. MRI dissemination in space is designated as the 
presence of at least three of the following criteria: 1) one Gd-enhancing brain lesion or nine T2-
weighted hyperintense brain lesions; 2) one infratentorial lesion; 3) one juxtacortical lesion; 4) three 
periventricular lesions. Notably, one spinal cord lesion can replace one brain lesion. MRI 
dissemination in time is regarded as the occurrence of at least one of the following criteria: 1) a Gd-
enhancing lesion demonstrated in a scan done at least three months after the onset of a relapse at a 
site different from attack; 2) a Gd-enhancing lesion or a new T2 lesion identified in a follow-up 
scan done after additional three months.  
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Development of autoimmunity in MS   
The complex approach adopted for the diagnosis of MS reflects the uncertainty about disease 
pathogenesis. MS is currently hypothesized to be an autoimmune disease directed by autoreactive 
CD4+ Th1 cells which traffick across the BBB and migrate into the CNS after activation (Hemmer 
et al, 2004; Sospedra and Martin, 2005; Hauser and Oksenberg, 2006). These cells seem to regulate 
a coordinated attack of both innate and acquired immune responses directed against myelin proteins 
which includes monocytes, macrophages, NK cells, B cells and CD8+ T cells and results in CNS 
inflammation promoting myelin damage and axonal injury. In this context, it is generally believed 
that the initiation of MS autoimmunity takes place in the periphery due to failure of self-tolerance 
since T and B cells are primed in the peripheral lymphoid tissue after the presentation of neural 
antigens released from the CNS performed by meningeal and choroid plexus-associated dendritic 
cells which provide for transfer of these proteins from the brain to the cervical lymph nodes via the 
nasal lymphatics of the cribriform plate (Hemmer et al, 2004; Sospedra and Martin, 2005; Hauser 
and Oksenberg, 2006). Under physiologic circumstances, myelin-specific autoreactive T cells are 
detectable in peripheral blood of healthy individuals since they are part of normal T cell repertoire 
(Sospedra and Martin, 2005). These autoaggressive T cells are usually eliminated or inactivated 
through the mechanisms of peripheral immunologic tolerance by which autoreactive T cells that 
recognize self antigens become incapable of responding to these proteins. Therefore, brain antigens 
can be recognized as non-self by a dysfunction of regulatory immune cells (“autoimmune 
hypothesis”) or by a reaction with proteins released from the CNS after primary degeneration 
(“degeneration hypothesis”) or infection (“infection hypothesis”) (Hemmer et al., 2004; Sospedra 
and Martin, 2005). The current hypotheses for MS pathogenesis are described in Figure 4. 
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Figure 4. A schematic view of the current hypotheses on the mechanisms responsible for the 
initiation of multiple sclerosis (MS) autoimmunity. Under normal conditions, brain proteins are 
released in the cerebrospinal fluid (CSF) as the result of physiological processes of remodeling and 
tissue repair (1a). In MS, tissue injury due to infection (1b) or degeneration (1c) increases the 
shedding of central nervous system (CNS) antigens in the CSF including cryptic epitopes that are 
unknown for the immune system. These neural CSF proteins are captured by meningeal and choroid 
plexus dendritic cells (2) that transport them (3) to perivascular spaces of the nasal olfactory artery 
(4) and then, via nasal lymphatics of the cribriform plate, to peripheral cervical lymph nodes (5). 
Within the secondary lymphoid organs, brain protein coming from the CNS can be recognized as 
non-self by infection-mediated interactions (molecular mimicry, epitope spreading, bystander 
activation) or a dysfunction of regulatory immune cells. It follows the priming of naive autoreactive 
T and B cells that become activated and undergo clonal expansion (6). Subsequently, these cells 
recirculate into the CNS where the re-encounter and the recognition of the cognate antigen lead to 
the development of an intrathecal inflammatory response (7) that produces demyelination and 
axonal loss (8). Over time, inflammatory microenvironment promotes the progression of 
neurodegeneration, generating irreversible disability. Conversely, cumulative axonal destruction 
can occur independently of neuroinflammation and may cause irreversible disability (9) (modified 
from Fainardi and Castellazzi, 2010). 
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Progression of the disability in MS 
Whatever the mechanisms promoting the initiation of the disease are unknown, two different 
temporally distinct stages can classically be identified in MS (Steinman, 2001):  
1) an early inflammatory phase due to autoimmune-mediated demyelination leading to clinical 
recurrence of relapses and remissions (RR MS form);  
2) a late degenerative phase due to axonal loss leading to clinical chronic progression (SP and PP 
MS forms).  
This model assumes that, in early RR MS clinical course, Th1-mediated inflammatory responses 
induce clinical relapses promoting demyelination mainly through the release of toxic mediators by 
activated macrophages and microglia and the production of antibodies by B cells. As axonal injury 
is present early in the disease, neurodegeneration begins in the same period due to Th1-related 
inflammatory mechanisms such as cytotoxic activity of CD8+ T cells and Ca
++
-dependent 
glutamate excitotoxicity driven by activated macrophages and microglial cells. On the contrary, the 
resolution of neuroinflammation is followed by clinical remissions. Over time, the recurrence of 
several inflammatory events creates a persistent pro-inflammatory intrathecal microenvironment 
maintaining a permanent axonal loss in association with the reduced support for the axons and the 
destabilization of axon membrane potentials which follow myelin damage. When the compensatory 
immunoregulation fails, the cumulative axonal injury leads to the irreversible progression of 
neurological disability (Sospedra and Martin, 2005; Hauser and Oksenberg, 2006). The traditional 
view of MS as a “two-stage disease” is further challenged by radiological studies which confirm the 
heterogeneity of MS, due to the occurrence of different lesional patterns underlying distinct 
mechanisms of tissue injury, and show that inflammatory and degenerative phases can coexist 
(Charil and Filippi, 2007). For this reason, it has been proposed that MS may be a “simultaneous 
two-component disease” (Charil and Filippi, 2007) in which neuroinflammation and 
neurodegeneration could represent two distinct events occurring separately. From the clinical point 
of view, MS disease severity and progression could be scored by a numerical scale, the Kurtzke’s 
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Expanded Disability Status Scale (Kurtzke, 1983) in which zero corresponds to a normal 
neurological examination and 10 corresponds to death due to MS. The EDSS quantifies disability in 
eight functional systems:  pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, 
cerebral, other. Neurologists assign a score in each of these.  
 
Figure 5. Kurtzke’s expanded disability status scale (EDSS) (http://www.msdecisions.org.uk). 
  
Infection theory in MS 
Epidemiological studies indicate that exposure to an environmental factor, such as an infectious 
agent, in combination with genetic predisposition could be implicated in MS pathogenesis (Casetta 
and Granieri, 2000; Sospedra and Martin, 2005, Ascherio and Munger, 2007). The risk of MS is 
enhanced by the presence of specific genes on chromosome 6 in the area of MHC, HLA in humans. 
In particular, HLA-DR and HLA-DQ genes, which are involved in antigen presentation, are 
strongly associated to the development of the disease. However, although  the risk of the disease is 
higher in monozygotic than in dizygotic twins (about 30% and 5%, respectively), the low 
concordance rate obtained in identical twins suggests that non-genetic factors can contribute to the 
initiation of the disease. In this setting, the potential role for an infectious agent in MS pathogenesis 
is supported by descriptive epidemiological studies showing a non homogeneous geographical 
  20 
distribution, a variation in trend in some areas of the world, the evidence of possible clusters and a 
change of risk in migrants. A primary encounter with this microbial agent could occur in young 
genetically susceptible adults, who subsequently develop the disease. This antecedent infection is 
believed to trigger autoimmune events operating in MS after reactivation. There is also substantial 
clinical and experimental evidence supporting the possible involvement of an infectious agent in the 
pathogenesis of MS:  
- non specific systemic infections, particularly those affecting the upper respiratory tract, represent a 
risk factor for relapse in MS patients (Correale et al, 2006); 
- CSF oligoclonal bands are present not only in MS, but also in chronic bacterial, fungal, parasite 
and viral CNS infections in which this intrathecal oligoclonal antibody response is directed against 
the causative agent (Contini et al, 1998; Fainardi et al, 2001); 
- CNS viral infection are able to induce inflammation and demyelination in humans and in MS 
animal models, as demonstrated by JC papovavirus-mediated multifocal leukoencephalopathy and 
measles-induced subacute sclerosing panencephalitis (Sospedra and Martin, 2005; Lipton et al, 
2007); 
- MHC class I-restricted CD8+ T cell response, usually triggered by viruses, takes part in MS 
immune deregulation (Skulina et al, 2004).  
Infectious agents could generate an autoimmune response within the CNS by various mechanisms 
including antigen-specific and non antigen-specific pathways such as:  
a) molecular mimicry;  
b) epitope spreading;  
c) bystander activation;  
d) cryptic epitopes;  
e) superantigens (Scarisbrick and Rodriguez, 2003; Sospedra and Martin, 2005).  
Molecular mimicry is a cross-reactive T cell immune response between microbial and CNS self-
antigens, due to their sequence homology, and is antigen-specific. Epitope spreading describes a 
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spreading of an antigen-specific T cell immune response from infectious antigens to multiple CNS 
self-epitopes which are released as a consequence of microbial-mediated brain inflammation. 
Bystander activation consists of a non antigen-specific T cell immune reaction targeting CNS self-
antigens promoted by infected T cells secreting pro-inflammatory cytokines and chemokines. 
Cryptic epitopes are antigens usually sequestered in the brain tissue which are unveiled and 
recognized as non-self by antigen-specific T cells after direct infection of target cells. Superantigens 
are microbial molecules originating primarily from bacteria or viruses which stimulate the 
activation of T cells cross-reacting with CNS self-antigens in an antigen-independent manner.  
 
Epstein-Barr virus 
Epstein-Barr virus (EBV) is a ubiquitous human γ-herpesvirus that has the unique ability to infect, 
activate, and latently persist in B lymphocytes for the lifetime of the infected host. EBV infects 
naive B cells in the tonsils during primary infection and drives the infected B cell out of the resting 
state to become an activated B blast, and then exploits the normal pathways of B cell differentiation 
so that the B blast can become a latently infected resting memory B cell (Thorley-Lawson and 
Gross, 2004). To achieve this, the virus deploys a series of different latency transcription 
programmes (Thorley-Lawson and Gross, 2004). In the latency III or “growth” programme all viral 
proteins are expressed: Epstein-Barr nuclear antigens (EBNA) 1, 2, 3A, 3B, 3C, and LP and the 
latent membrane proteins (LMP) 1, 2A, and 2B. This activates the naive B cell to become a B blast, 
which then enters a germinal centre in the tonsils where it down-regulates the expression of the 
EBNA proteins 2, 3A, 3B, 3C, and LP. The continuing expression of EBNA1, LMP1, and LMP2 
(latency II or “default” programme) allows the infected B cell to progress through a germinal centre 
reaction to become a memory B cell. The EBV-infected memory B cell expresses no viral proteins 
except during cell division, when it expresses only EBNA1 (latency I). The lack of viral protein 
expression allows the virus to persist in memory B cells notwithstanding the immune surveillance. 
Latently infected memory B cells can return to the tonsils and then differentiate into plasma cells, 
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which initiates the lytic (replicative) transcription programme with the production of infectious 
virus (Laichalk and Thorley-Lawson, 2005). It is remarkable that, while in normal B cell 
differentiation naive B cells are activated by antigens through the B cell receptor (BCR) and by T 
cell help through the CD40 receptor, in EBV-infected naive B cell LMP2A and LMP1 mimic the 
antigen-activated BCR and the activated CD40 receptor, respectively (Pender, 2011).  
 
Epstein-Barr virus and multiple sclerosis  
Seroepidemiological studies have shown that there could be a strong association between MS and 
EBV (Handel et al, 2010). In a meta-analysis of case-control observational studies published before 
January 2009 (Santiago et al, 2010) the authors found an association between MS and an exposure 
to EBV particularly sustained by the levels of anti-viral capsid antigen (VCA) IgG (odds ratio [OR] 
= 5.5; 95% confidence interval [CI] = 3.37–8.81; p < 0.0001) and anti-EBNA-1 IgG (OR = 12.1; 
95% CI = 3.13–46.89; p < 0.0001). No significant association were found when studying anti-early 
antigen (EA) IgG (OR = 1.3; 95% CI = 0.68–2.35; p = 0.457). A past infectious mononucleosis 
(IM) was found to be more frequent and the seroprevalence of anti-EBNA-1 and anti-VCA IgG  
higher in MS patients than in controls (Handel et al, 2010; Santiago et al, 2010; Almohmeed et al, 
2012). High serum levels of anti-EBNA-1 IgG increased the risk of developing MS (Ascherio and 
Munger 2010), correlated with disease activity (Farrell et al, 2009), predicted the conversion from 
clinical isolated syndrome (CIS) to definite MS and could be used as a prognostic marker for 
disease conversion and disability progression (Lünemann et al, 2010). Elevated serum 
concentrations of anti-VCA IgG were related to grey matter atrophy (Zivadinov et al, 2010).
 
The 
role of EBV in MS pathogenesis was in part supported by the experimental demonstration that EBV 
proteins and myelin-basic protein epitopes share structural similarity (Lang et al, 2002).
 
However, 
conflicting results have been obtained in cellular, molecular and neuropathological studies since, in 
MS patients, blood EBV-specific CD8+ T cell response was found increased, decreased or absent, 
cerebrospinal fluid (CSF) and blood EBV DNA load was high or not measurable and the detection 
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of EBV-infected B cells in brain lesions was inconsistent (Santiago et al, 2010; Ascherio and 
Munger, 2010; Lünemann, 2012). Controversial findings also emerged from the quantitative and 
qualitative analysis of intrathecal synthesis of anti-EBV IgG in MS. In particular, an intrathecal 
synthesis of anti-EBV IgG determined by the calculation of the specific antibody index (AI)  was 
increased (Pohl 2010) or not significantly augmented (Castellazzi et al, 2010; Sargsyan et al, 2010; 
Villegas et al, 2011) in MS patients. Moreover, intrathecally synthesized EBV-specific IgG were 
not associated to MS after normalization with total IgG (Jafari et al, 2010) and were considered as a 
part of the polyspefic immune response that occur in MS in another study (Otto et al, 2011). EBV-
specific oligoclonal IgG bands (OCB) were found in almost 100% of MS postmortem CSF (Serafini 
et al, 2007), in a third of the MS CSF (Rand et al, 2000) and in some patients after screening in a 
protein library (Cepok et al, 2005b). However, when EBV-specific IgG OCB were determined in 
paired CSF and serum samples only 13% of MS patients showed an intrathecal synthesis (Virtanen 
et al, 2013) or, on the contrary, almost half of the patients had a systemic EBV-specific immune 
respone without intrathecal production (Franciotta et al, 2011). Nevertheless, none of the previous 
studies investigated the affinity distributions of intrathecally released anti-EBV antibodies.  
 
Biomarkers and multiple sclerosis 
According to literature the following working definitions were adopted in this study (Bielekova and 
Martin, 2004): 
- a “biomarker” is a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes or pharmacological responses to a therapeutic 
intervention; 
- a “type 0 biomarker” is a marker of the natural history of a disease and correlates longitudinally 
with known clinical indices; 
- a “type I biomarker” captures the effects of a therapeutic intervention in accordance with its 
mechanism of action. 
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The requirements for a biomarker, i.e. validity, specificity and ease of measurement, will be quite 
different depending on its intended use (e.g. preclinical versus early clinical and late clinical stages) 
and on the body compartment in which we intend to measure the biomarker.  
- Blood is relatively simple to collect. The amount collected depends on the assay used and mainly 
ranges in few millilitres. The main disadvantage is the diurnal variation of many soluble markers 
and invasiveness of the collection.  
- CSF may better reflect the relevant in flammatory process due to its proximity to inflammatory 
lesions in the CNS. Moreover CSF collection does prevent biological degradation of excreted 
markers by the liver or by renal excretion. However CSF collection is an invasive, although 
relatively benign, procedure that is widely used mainly for diagnostic purpose. 
 
Cerebrospinal fluid analysis in the diagnosis of multiple sclerosis 
In 1994, the Committee of the European Concerted Action for Multiple Sclerosis (Charcot 
Foundation) organised five workshops to discuss CSF analytical standards in the diagnosis of 
multiple sclerosis. This consensus report from 12 European countries summarises the results of 
those workshops (Andersson et al, 1994).  
Briefly, CSF must be analysed in parallel with corresponding serum. Lumbar puncture, whenever 
possible, is performed in the morning, together with blood sampling. All samples are collected in 
sterile conditions, glasssyliconized/polypropylene tubes. Blood samples should not be hemolysed, 
or lipemic and CSF samples should be analysed from a non-traumatic lumbar puncture. CSF 
samples should be evaluated for appearance and colour, before and after centrifugation. Appearance 
and colour are expressed with qualitative scales (for example, ‘‘crystal-clear’’, ‘‘turbid’’, ‘‘cloudy’’ 
for appearance, and ‘‘colorless’’, ‘‘xanthochromic’’, ‘‘erythrochromic” for color) and CSF cells 
should be counted and processed within 2 h of sampling. Biochemical analysis are performed on 
supernatants of centrifuged CSF, and on paired serum samples. Glucose, which is measured with 
colorimetric methods, should be reported as a percentage ratio or as concentration. The 
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determination of serum and CSF albumin with the calculation of albumin ratio, or albumin quotient, 
is the most accurate index for blood-brain-barrier damage, and should replace the determination of 
CSF total protein (Tibbling et al, 1977). Intrathecal IgG synthesis should be expressed with the use 
of non-linear functions, such as Reiber and Felgenhauer’s formulae (Clin Chim Acta 1987), which 
take into account blood-brain-barrier functionality. To decrease analytical imprecision, serum and 
CSF albumin and IgG must be determined on the same analytical session. Methods allowed for 
albumin and IgG determination are nephelometry, turbidimetry and radial immunodiffusion. There 
is complete agreement that isoelectric focusing (IEF) on agarose gels followed by immunoblotting 
for detecting the presence of oligoclonal IgG bands should be the “gold standard” method for the 
determination of an intrathecal synthesis of immunoglobulin (Anderson et al, 1994, Freedman et al 
2005, Franciotta et al, 2005). The European consensus report, which described 5 patterns, 
represented a cornerstone for the interpretation of IEF results (Andersson et al, 1994) (Figure 6): 
a) “Normal CSF”, characterized by the presence of a diffuse polyclonal IgG background; 
b) “Local synthesis”, characterized by the presence of at least two OB restricted to CSF; it suggests 
an intrathecal IgG-specific immune response. 
c) “Mixed”, characterized by the presence of restricted OB with additional, identical bands in CSF 
and serum; it is an index of both intrthecal and systemic immune response. 
d) “Mirror”, with identical OB in CSF and serum; It suggests a general immune system activation 
extended to CNS due to the presence of BBB disfunction. 
e) “Paraprotein bands”, that is monoclonal bands in CSF and serum; this appears only in 
monoclonal gammopathy.  
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Figure 6. Serum-CSF oligoclonal IgG patterns. A) “Normal” (polyclonal); B) “intrathecal 
synthesis”; C) “mixed”; D) “mirror”; E) “paraproteinemic”. S = serum; CSF = cerebrospinal fluid. 
 
Intrathecal synthesis of antigen-specific antibody (quantitative approach) 
An intrathecal synthesis of antigen-specific antibody could be quantified by combining 
immunoassay with a sophisticated evaluation method that involves calculating the ratio between 
CSF/serum quotient for specific antibodies (Qspec) and total IgG (QIgG) (Reiber and Lange, 1991). 
This antibody Index (AI = Qspec/QIgG) discriminates between blood-derived and brain-derived 
pathological antibodies taking into account the permeability fo the BBB. A simple approach to the 
topic is as follows: a) total IgG concentration in serum and CSF is determined; b) serum sample is 
diluted to the same CSF total IgG concentration; c) both CSF and serum samples are tested with 
immunoassay for the specifc antigen and results reported in OD units; d) antibody concentrations 
can be determined by using a reference standard curve and plotting the OD value to obtain the 
respective arbitrary unit (AU) value. See materials and methods section for details.  
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Intrathecal synthesis of antigen-specific antibody (qualitative approach) 
It has been recognized for a number of years that patients with MS produce locally synthesized IgG 
within the CNS (Anderson et al, 1994). A small proportion of these antibodies react against specific 
viral or bacterial antigens (Reiber and Lange, 1991). However, the target of this oligoclonal 
immune response is still unknown or controversial (Serafini et al, 2007; Fainardi et al, 2009). 
Besides, during CNS infection, it has been shown that CSF IgG OB are specific for  the causative 
antigen (Fainardi et al, 2001). Qualitative methods provide the most sensitive means of identifying 
an intrathecal immune response (Anderson et al, 1994) and these can be adapted to detect antigen-
specific IgG (Fainardi et al, 2001; Fainardi et al, 2009). Intrathecal synthesis of specific antibodies  
can be demonstrated by antigen spefic immunoblotting (ASI). Briefly, after isoelectric separation of 
CSF and serum protein into an agarose gel, the gel is onto a nitrocellulose membrane precoated 
with the antigen of interest. See material and methods section for details. Four antigen-specific IgG 
oligoclonal bands can be identified considering paired CSF and serum samples: normal CSF, local 
synthesis, mixed and mirror (Fainardi et al, 2001; Fainardi et al, 2009). The paraproteinemic pattern 
is here absent. 
 
Antibody affinity 
The assessment of the virus-specific antibody production in the brain is crucial to understand the 
effective relevance of a pathogen in MS because it is well known that, while in MS a polyspecific 
intrathecal immune response composed by anti-viral low-affinity antibodies occurs, in infectious 
diseases intrathecally synthesized high-affinity antibodies, of which at least 30% specifically 
directed against the causative agents, predominate (Sindic et al, 1994; Conrad et al, 1994; Luxton et 
al, 1995). It has been demonstrated that in the course of an infection, the process of immune 
maturation requires a progressive increase in antibody affinity that leads to an intensive production 
of high-affinity antibodies specifically directed against the causative pathogen (Luxton et al, 1995). 
This consist in a kind of molecular Darwinism in which the best “fit” of various antibodies will 
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“survive” and/or proliferate over the other antibodies and thus along with the classical increase in 
titres of antibody, there is a parallel increase in affinity. Since the bonds which hold the antigen in 
the “cleft” on the antibody (between the heavy and light chain variable regions) are primarily 
hydrogen bonds, various molecules which can “chelate” these protons are used in successively 
increasing concentrations to effectively dissociate the bonds between antigen and antibody. 
Examples include negatively charged anions (such as the iodide ion in NaI) or sodium thioyanate 
(NaSCN) where the thiocyanate anion is also effective in “chelating” the protons of the hydrogen 
bonds. 
 
Treatment with TYSABRI® 
Natalizumab (Tysabri, Biogen Idec Inc, Cambridge, Massachusetts, USA) is a selective adhesion 
molecule inhibitor that blocks α4 integrin, which is expressed on the surface of lymphocytes and is 
required for endothelial adhesion, facilitating migration of peripheral blood lymphocytes into the 
central nervous system (Polman et al, NEJM 2006). In a 2-year, phase 3 study of patients with 
relapsing-remitting multiple sclerosis (RRMS), natalizumab monotherapy demonstrated consistent 
efficacy in the overall study population and across multiple subgroups of patients predefined on the 
basis of demographic and baseline disease characteristics, including age, sex, number of brain MRI 
lesions, disability status and number of relapses in the prior year. With Determination dated 7 
December 2006 (GU n. 292 del 16.12.06), the Italian Drug Agency (AIFA) has implemented a 
centralized European approval (Determination/C no. 115/2006) of the medicinal product 
TYSABRI® (Natalizumab) and established the system of dispensation and the class of 
reimbursement paid by the national health system. TYSABRI® is licensed as disease modifying 
monotherapy in relapsing-remitting MS to prevent relapses and slow the progression of disability. 
For safety reasons, the treatment is restricted to specific groups of patients:  
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1. Patients with relapsing-remitting MS (RRMS) who have not responded to a full and adequate 
course of therapy with immunomodulatory therapies currently approved for RRMS. The patient 
must meet the following characteristics:  
a) diagnosis of relapsing-remitting MS;  
b) treatment with immunomodulatory therapy for at least twelve months (the period may be shorter 
if the lack of response to treatment is clearly documented in a shorter period of time);  
c) the presence of at least two relapses in the last year in therapy, or;  
d) the presence of a relapse in the last year in therapy with incomplete recovery and residual 
disability of not less than 2 on the EDSS;  
e) the presence of at least nine T2 lesions on MRI, or;  
f) presence of at least one gadolinium-positive lesions on MRI. 
2. Patients with severe relapsing-remitting MS with rapidly evolving. The patient must meet the 
following characteristics:  
a) diagnosis of relapsing-remitting MS;  
b) the presence of at least two relapses in the last year with incomplete recovery and residual 
disability of not less than 2 on the EDSS;  
c) the appearance of new T2 lesions (refer to changes in both numerical and volumetric) with 
respect to a MRI examination performed no later than twelve months ago, or the appearance of 
gadolinium-positive lesions compared to a MRI done no more than twelve months earlier. 
TYSABRI® 300 mg should be administered by intravenous infusion once every 4 weeks. The use 
of TYSABRI® has been associated with an increased risk of progressive multifocal 
leukoencephalopathy (PML), an opportunistic infection caused by the JC virus, which can be fatal 
or cause serious disability. 
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OBJECTIVES OF THE STUDY 
The present study focused on two distinct aspects. 
1) The association between Epstein-Barr virus and multiple sclerosis at the time of diagnosis. 
The first part of the study aimed to investigate the association between MS and EBV through an in-
depth analysis of the virus specific antibody response in a large cohort of relapsing-remitting MS 
patients, categorized according to clinical and magnetic resonance imaging disease activity, and, as 
controls, in patients with other neurological inflammatory diseases (OIND) and non-inflammatory 
neurological disorders (NIND). In these different groups, we determined: a) CSF and serum levels 
of anti-EBNA-1 and anti-VCA IgG, considered as latent and lytic markers, respectively, by using 
enzyme-linked immunosorbent assay (ELISA); b) intrathecal synthesis of anti-EBV IgG by means 
of Antibody Index (AI): quantitative determination; c) intrathecal synthesis of anti-EBV oligoclonal 
IgG, employing an antigen specific immunoblotting (ASI) protocol: qualitative determination; d) 
affinity distributions of anti-EBV antibodies utilizing a modified ELISA method; e) affinity 
distributions of CSF EBV-specific oligoclonal IgG bands using a modified ASI method. 
2) The role of EBV-specific antibodies as biomarkers during disease modifying therapy. 
The second goal of the research was to verify the use of serum EBV-specific antibodies as a 
biomarker for the response to treatment with TYSABRI® in a cohort of relapsing-remitting MS 
patients during the first 15 months of therapy. 
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MATERIALS AND METHODS 
 
Study design 
The first part of the study included 100 consecutive patients with relapsing-remitting definite MS 
(RRMS) according to the currently accepted criteria (Polman et al. 2011) (Table 3).  
 
Table 3. Demographic, clinical, radiological and CSF characteristics in 100 patients with relapsing-
remitting multiple sclerosis (RRMS). 
Sex: F/M 70/30 
Age, years: mean ± SD 37.3 ± 10.6 
Disease duration, months: mean ± SD 30.5 ± 46.6 
Disease severity, EDSS: mean ± SD 2.0 ± 1.3 
CA MS: n/total (%) 77/100 (77%) 
CS MS: n/total (%) 23/100 (23%) 
Gd+ MS: n/total (%) 37/100 (37%) 
Gd- MS: n/total (%) 63/100 (63%) 
Blood-CSF-barrier dysfunction, QAlb: positive/total (%) 18/100 (18%) 
Intrathecal IgG synthesis, IgG Index: positive/total (%) 71/100 (71%) 
CSF-restricted oligoclonal IgG bands: positive/total (%) 84/100 (84%) 
EDSS =  Expanded disability status scale; CA = Clinically Active (presence of relapse at entry); CS 
= Clinically Stable (absence of relapse at entry); Gd+ = MRI appearance of gadolium enhancing 
lesions; Gd- = no MRI evidence of gadolium enhancing; QAlb = CSF/serum albumin quotient; IEF 
= isoelectric focusing followed by IgG-specific immunoblotting. 
 
At the time of sample collection: a) disease severity was scored using Kurtzke’s Expanded 
Disability Status Scale (EDSS) (Kurtzke 1983); b) disease duration was scored and expressed in 
months; c) presence of relapse was recorded as clinical activity; d) lesions showing Gd-
enhancement on T1-weighted scans were defined as MRI activity.  
  32 
Table 4. Demographic and clinical features in other inflammatory neurological disorders (OIND) 
and non-inflammatory neurological disorders (NIND). 
Patients n  Sex Age (years) Type of disease 
  F M   
OIND 100 70 30 37.5 ± 10.7  
 29    Chronic inflammatory demyelinating 
polyneuropathy 
 18    Viral encephalomyelitis 
 18    Acute inflammatory demyelinating polyneuropathy 
 11    Bacterial meningitis 
 10    Optic neuritis 
 6    HIV encephalopathy 
 3    Neurolupus 
 3    NeuroSjogren 
 3    NeuroBechet 
NIND 100 70 30 38.1 ± 11.1  
 14    Transient ischemic attack 
 13    Epilepsy 
 12    Headache 
 10    Cervical spondylosis 
 10    Hereditary ataxia 
 9    Vascular dementia 
 9    Migraine 
 8    Amyotrophic lateral sclerosis 
 7    Compression neuropathy 
 4    Paresthesias 
 4    Alzheimer disease 
OIND =  Other Inflammatory Neurological Diseases; NIND = Non-Inflammatory Neurological 
Diseases. 
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One hundred patients with other inflammatory neurological disorders (OIND) and 100 subjects with 
other non-inflammatory neurological disorders (NIND) were selected as neurological controls 
(Table 4) who were age and sex matched to RRMS. Paired CSF and serum samples were 
prospectively collected at the Section of Neurology, University of Ferrara, and at the Operative Unit 
of Neurology, Azienda Ospedaliero-Universitaria di Ferrara, during the period from January 2007 
to December 2011 from RRMS, OIND and NIND patients. Samples were obtained for purposes of 
diagnosis and measured under exactly the same conditions. MS OIND and NIND patients were free 
of immunosuppressant drugs, including steroids, at the time of sample collection. CSF and serum 
IgG and albumin levels were measured by immunochemical nephelometry with the Beckman 
Immage 800 system (Beckman Instruments, Fullerton, CA, USA). In all patients, Blood-CSF-
barrier (B-CSF-B) dysfunction was determined by CSF/serum albumin quotient (QAlb) (Tibbling et 
al, 1977) and total IgG OCB by isoelectric focusing (IEF) (Franciotta et al, 2005).  
The second part of the study was focused on a cohort of MS patients treated with TYSABRI®. 
Patients were enrolled at the “Fondazione Istituto Neurologico C. Mondino” in Pavia: 
- 17 female: Age (mean ± SD)= 24.2 ± 7.1 years; EDSS (mean ± SD)= 1.5 ± 1.6; 
 - 3 male: Age (mean ± SD)= 29.0 ± 1.7 years; EDSS (mean ± SD) = 0.5 ± 0.9. 
Serum samples were collected at baseline and consecutively after 3, 6, 9, 12, 15, 18 and 21 months 
after the beginning TYSABRI® therapy. To exclude short-term drug effects, all samples were taken 
at least 12–36 h after TYSABRI® injection. None of the patients had been receiving corticosteroids 
when these samples were collected. The studies were both approved by the Regional Committee for 
Medical Ethics in Research. 
 
Magnetic Resonance Imaging analysis 
All MS patients underwent brain Magnetic Resonance Imaging (MRI) scans at entry on a 1-Tesla 
MRI unit (GE Signa Horizon, General Electric Medical Systems, Milwaukee, WI). Routinely used 
T1- weighted axial spin echo images were obtained approximately 10 min after intravenous 
  34 
injection of 0.1 mmol/kg of Gd-DTPA in each patient. All brain MRI scans were evaluated by one 
investigator blinded to clinical and sample data. 
 
Serum and CSF levels of anti-EBV antibodies 
CSF and serum concentrations of anti-EBNA-1 and anti-VCA IgG were measured by enzyme-
linked immunosorbent assay (ELISA) and expressed as arbitrary Units (AU) as published before 
(Castellazzi et al, 2010). The methods were based on the use of commercially available ELISA kits 
(NovagnostTM EBV-EBNA1 IgG and EBV-VCA IgG, cod. num. EBVG0580DB and  
EBVG0150DB, respectively). Briefly, a reference curve was generated in each assay using six 
serial dilutions of pooled high-positive serum samples ranging between 0.1 and 2.0 OD. CSF and 
corresponding serum prediluted with a range of 1:2-1:6 and 1:100-1:1200, respectively, were 
dispensed in duplicate into two microtiter plates, one precoated with highly purified EBV-EBNA-1 
and the other precoated with EBV-VCA. Reference curve was generated in each assay using the 
standard serial dilutions by plotting the standard well concentrations, expressed as AU, versus the 
relative OD values. The lowest and the upper standard values of each plate were considered as 
3.125 and 100 AU, respectively. The linear relationship between the AU values and the OD titers 
provides for easy extrapolation of concentration values. For each sample anti-EBNA-1 and anti-
VCA IgG concentrations were obtained by multiplying AU value for the corresponding dilution 
factor. Within-assay and between-assay precisions were determined after 10 repeated measured into 
the same plate and by repetition of the same sample in 10 consecutive plates, respectively. Both 
intra and inter-assay variations, expressed as coefficient of variations (CV)%, were less than 8% for 
both anti-EBNA-1 and anti-VCA IgG. 
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Calculation of EBNA-1 and anti-VCA IgG -specific Antibody Index 
According to literature (Reiber and Lange, 1991), Antibody Index (AI) means the ratio between 
CSF and serum AU values (QSpec) and CSF/serum total IgG levels expressed as mg/dl (QIgG) in 
accordance to the formula: 
AI = QSpec/QIgG     (1) 
with QSpec =  AUCSF/AUserum and QIgG = IgGCSF/IgGserum 
In the case of intrathecal synthesis of total IgG, QIgG appeared more elevated than Reiber’s 
hyperbolic discrimination line (QLim). QLim represented the completely blood-derived CSF total IgG 
fraction calculated from the individual QAlb of a single patient. Therefore, owing to the introduction 
of this barrier-related correction of the QIgG, the ratio became between QSpec and QLim in agreement 
with the formula: 
AI = QSpec/QLim     (2)          
with QLim  =   0.93 √  (QAlb)
2
 + 6·10
-6
  – 1.7·10
-3    
Therefore, to avoid false-negative results Equation 1 (QIgG < QLim) is used when no significant 
intrathecal total IgG synthesis occurs, while Equation 2 (QIgG > QLim) was preferred in case of 
intense brain-derived total IgG production in CSF. EBV-specific intrathecal IgG synthesis was 
assumed for values of AI greater than 1.5 (Reiber and Lange, 1991; Castellazzi et al, 2010). 
 
Antigen-specific immunoblotting 
EBV-specific IgG OCB were investigated by antigen-specific immunoblotting (ASI) as reported 
elsewhere (Fainardi et al, 2009) using as target antigen a crude viral lysate containing a high 
concentration of EBV antigens, including VCA, EBNA, EA-D and EA-R. Briefly, equal amounts of 
CSF and serum samples, at the same IgG concentrations, were applied to the agarose gel. After IEF 
run, the gel was blotted onto a nitrocellulose sheet previously coated overnight at room temperature 
with EBV antigens (EBV antigen, cod. 11-511-248315-1, Genway, US) diluted in phosphate buffer 
(PBS) at the concentration of 100 µg/ml. The nitrocellulose membrane was then washed with 
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distilled water and subsequently saturated by incubation in physiologic solution containing 2% 
bovine serum albumine (BSA) for 30 minutes at room temperature, in constant agitation. The 
antigen-specific blotting was then performed according to the manufacturer’s instructions. 
Aspecific binding sites were further blocked in saline buffer containing 2% BSA for 30 minutes. 
The immunoblot was then incubated for 30 min at room temperature with peroxidase conjugated 
rabbit anti-human IgG diluted in 0.2% BSA saline. After another washing cycle with PBS, the blots 
were stained using peroxidase conjugated substrate of the kit according to the manufacturer’s 
instructions. The immunoblotting specificity was evaluated by testing CSF from a patient with 
subacute sclerosing panencephalitis that served as control antigen to exclude non-specific binding. 
No cross-reactivity to EBV was detected. As described for total OCB patterns, antigen-specific 
immunoblotting IgG banding patterns were categorized by two independent investigators. 
 
Determination of affinity distributions of EBV-specific antibodies  
CSF and serum affinity distributions of anti-EBNA-1 and anti-VCA IgG were measured at the same 
conditions by performing a ELISA protocol based on the employment of increasing concentrations 
of sodium thiocyanate (NaSCN) using the above-mentioned ELISA kits (Luxton and Thompson, 
1990; Fainardi et al, 2004) Briefly, 100 µl of each CSF or serum sample were added to 4 adjacent 
wells of each antigen-specific precoated ELISA microplate. After 1 h incubation at 37°C and three 
washing cycles, 4 consecutive dilutions of NaSCN (range: 0M, 1.25M, 2.5M, 5M, where 0M 
corresponded to 0.4% saline buffer) were applied into the wells corresponding to each patient for 10 
min at 37°C. After incubation, NaSCN was removed and after three washing cycles wells were 
blocked by adding 100µl per well of 2% BSA for 30 min at 37°C. After incubation, BSA was 
discarded and detection antibody reaction, colour development and absorbance recordings were 
performed as described in ELISA assay for serum and CSF levels of anti-EBNA-1 and anti-VCA 
IgG. Positive and negative controls and appropriate background wells (blanks) were included in 
each test. The average optical density between the blanks values was subtracted from all readings. 
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The affinity distribution histograms for EBNA-1 and VCA-specific IgG were obtained assuming 
that, for each CSF and serum sample, the results observed in the first well, in which NaSCN were 
absent, represented the total antigen-specific IgG. In each series of 4 subsequent NaSCN dilutions 
per row, we divided the difference in OD values between two successive wells (e.g. well 1 and well 
2) by OD values of the total antigen-specific IgG, and multiplied by 100. In this way, the variation 
in OD values between two subsequent wells was expressed as percentage of OD values of the total 
antigen-specific IgG measured in the first well. According to Luxton and coworkers (Luxton et al, 
1995) the difference in OD values between two consecutive wells reflected the proportion in which 
the bounded IgG molecules were reduced by the higher concentration of NaSCN dispensed in the 
two wells, and the corresponding percentage was considered as the Relative Affinity (RA) of 
antibodies. When OD values measured in the well with higher levels of NaSCN were slightly 
greater compared to those detected in the adjacent well with lower levels of NaSCN, then it was 
assumed to be equivalent and RA thus assumed to be zero. When positive OD values were still 
measurable in the wells with highest concentration of NaSCN (5M in the fourth well), we compared 
these OD values with those of a simulated following well which was considered to be zero. Based 
on this principle, we obtained an RA value showing the proportion of antigen-specific IgG which 
was not removed by the highest concentration (5M) of NaSCN, and then the highest antibody 
affinity. On this principle, for each sample, we determined:  
- RA1: percentage of IgG removed by 1.25M NaSCN;  
- RA2: percentage of IgG removed by 2.5M NaSCN;  
- RA3: percentage of IgG removed by 5M NaSCN;  
- RA4: percentage of IgG remaining after treatment with 5M NaSCN.  
CSF and serum samples with RA value more than 2.5% from well number four containing the 
highest concentration (5M) of NaSCN (RA4) were considered as having high-affinity anti-EBNA-1 
and anti-VCA IgG, whereas CSF and serum samples with RA4 value equal or less than 2.5% were 
regarded as showing low-affinity anti-EBNA-1 and anti-VCA IgG. In addition, to increase the 
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sensitivity in the detection of antibody binding affinity, the affinity of anti-EBNA-1 and anti-VCA 
IgG was also defined in all the samples by Affinity Ratio (AR), a single numerical value which 
relates the percentages of high affinity antibodies (RA4) to the percentages of low affinity 
antibodies (RA1): 
Affinity Ratio (AR) = RA4/RA1 x 100 
 
Determination of EBV-specific IgG OCB affinity   
Affinity of EBV-specific IgG OCB was evaluated following a previously published immunoblotting 
protocol that employed increasing concentrations of NaSCN (Chapman et al, 2006). CSF samples 
were loaded in two parallel agarose gels (two groups of four samples per gel). IEF were performed 
for both gels at the same time and conditions in order to reduce errors due to inter-assay variation. 
After focusing, the gels were blotted onto the EBV precoated Ultrabind 450 membrane (Gelman, 
UK) for 45 minutes under a 1 kg weight. Antigen precoating was performed overnight as illustrated 
in ASI protocol. Ultrabind membrane was used due to its ability to bind covalently antigens which 
could be stripped by NaSCN from the nitrocellulose membrane, where their bind is usually non-
covalent. Each membrane was then divided into two identical parts each with four samples. Each 
part was incubated with four different concentrations of NaSCN (0M, 1.25M, 2.5M, 5M, 
respectively) for 30 min at room temperature. The membranes were then washed in running tap 
water to remove any residual NaSCN and reincubated in blocking solution (BSA) for 30 minutes to 
ensure that any binding sites uncovered by the NaSCN incubation were blocked. Conjugated rabbit 
anti-human IgG diluted in 0.2% BSA saline was then added and after another washing cycle with 
PBS, the blots were stained using peroxidase conjugated substrate (ASI protocol). Afterwards, the 
affinity of EBV-specific IgG OCB was judged qualitatively based on the intensity of the bands 
detected by visual inspection. A persistence of EBV-specific IgG OCB at 5M NaSCN was 
interpreted as suggestive of high affinity. 
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Statistics 
Statistic analysis was performed with GraphPad Prism®. After checking data for normality by using 
the Kolmogorov–Smirnov test, normality of data distribution was rejected in several variables. 
Therefore, statistical analysis was performed by a non-parametric approach. More precisely, 
continuous variables were compared using the Kruskal–Wallis test followed by the Mann–Whitney 
U test, whereas categorical variables were compared by means of Chi-square test (χ2). Correlation 
between continuous variables were assessed by Spearman rank correlation coefficient test. 
Bonferroni correction was utilized for multiple comparisons. A value of p < 0.05 was accepted as 
statistically significant. 
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RESULTS (1) 
 
CSF and serum levels and intrathecal synthesis of anti-EBV IgG in RRMS patients and 
controls 
Detectable CSF levels of anti-EBNA-1 IgG were statistically more frequent in RRMS than in NIND 
(p<0.05), whereas measurable CSF amounts of anti-VCA IgG were more frequent in OIND than in 
RRMS (p<0.001) without any significant differences among RRMS, OIND and NIND for serum 
quantifiable levels of anti-EBNA-1 and anti-VCA IgG (Table 5).  
 
Table 5. Frequency of CSF and serum samples with detectable levels of anti-EBNA-1 and anti-
VCA IgG in patients with relapsing-remitting multiple sclerosis (RRMS), other inflammatory 
neurological disorders (OIND) and non-inflammatory neurological disorders (NIND). 
 anti-EBNA-1 IgG  anti-VCA IgG 
 CSF serum  CSF serum 
RRMS (n=100) 96/100 (96%)* 99/100 (99%)  65/100 (65%) 90/100 (90%) 
OIND (n=100) 91/100 (91%) 96/100 (96%)  86/100 (86%)^ 94/100 (94%) 
NIND (n=100) 86/100 (86%) 94/100 (94%)  74/100 (74%) 90/100 (90%) 
CSF anti-EBNA-1 IgG (Chi-square with Bonferroni correction): *RRMS vs. NIND (p<0.05); CSF 
anti-VCA IgG (Chi-square with Bonferroni correction): ^OIND vs. RRMS (p<0.001). 
 
As listed in Figure 7, CSF levels of anti-EBNA-1 and anti-VCA IgG were statistically different 
among RRMS, OIND and NIND (Kruskal-Wallis: p<0.0001 and p<0.01, respectively). 
Significantly different levels of anti-EBNA-1 and anti-VCA IgG among RRMS, OIND and NIND 
were also observed in serum samples (Kruskal-Wallis: p<0.001 and p<0.05, respectively). 
Specifically, CSF anti-EBNA-1 IgG mean levels were more elevated and in RRMS (p<0.01) and in 
OIND (p<0.05) than in NIND (Panel A). CSF mean levels of anti-VCA IgG were higher in OIND 
than in RRMS and NIND groups (p<0.01 and p<0.0001, respectively) (Panel B). Serum anti-
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EBNA-1 IgG mean levels were more elevated in RRMS than in OIND and NIND (p<0.0001) 
(Panel C). Conversely, no significant differences were found for serum anti-VCA IgG mean levels 
among the groups examined (Panel D). When RRMS patients were grouped according to clinical 
and MRI activity, no statistical differences were observed between RRMS patients with and without 
clinical and MRI evidence of disease activity for CSF and serum mean concentrations of anti-
EBNA-1 and anti-VCA IgG.  
 
Figure 7. CSF and serum levels of anti-EBNA-1 and anti-VCA IgG in patients with relapsing-
remitting multiple sclerosis (RRMS), other inflammatory neurological disorders (OIND) and non-
inflammatory neurological disorders (NIND). AU = arbitrary units; CA = Clinically Active 
(presence of relapse at entry); CS = Clinically Stable (absence of relapse at entry); Gd+ = MRI 
appearance of gadolium enhancing lesions; Gd- = no MRI evidence of gadolium enhancing. CSF 
anti-EBNA-1 IgG levels (Mann–Whitney with Bonferroni correction): MS vs. NIND (p<0.01); 
OIND vs. NIND (p < 0.05) (Panel A). CSF anti-VCA IgG levels (Mann–Whitney): OIND vs. MS 
(p<0.0001); OIND vs. NIND (p<0.01) (Panel B). Serum anti-EBNA-1 IgG levels (Mann–Whitney 
with Bonferroni correction): MS vs. OIND (p<0.0001); MS vs. NIND (p<0.0001) (Panel C). No 
differences were found for serum anti-VCA IgG mean levels (Panel D). The boundaries of the 
boxes represent the 25th–75th quartile. The line within the box indicates the median. The vertical 
lines above and below the box correspond to the highest and lowest values, excluding outliers. 
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An inverse correlation (Spearman: r=-0.336) was found between serum anti-EBNA-1 IgG levels 
and EDSS. We did not observe further definite relationships between disease severity and duration 
and CSF and serum concentrations of anti-EBNA-1 and anti-VCA IgG in RRMS patients (Table 6).  
 
Table 6. Correlations between CSF and serum anti-EBNA-1 and anti-VCA IgG and severity of the 
disease, expressed by EDSS, and the disease duration, expressed in months. 
 EDSS Disease duration (months) 
CSF anti-EBNA-1 IgG levels (AU) r =  - 0.1642 r = 0.1181 
CSF anti-VCA IgG levels (AU) r = 0.2294 r = 0.1184 
Serum anti-EBNA-1 IgG levels (AU) r = - 0.336* r = 0.0963 
Serum anti-VCA IgG levels (AU) r = 0.1901 r = 0.1443 
EDSS =  Expanded disability status scale; AU = arbitrary units. Spearman: *p<0.001 
 
An intrathecal synthesis of anti-EBNA-1 IgG and anti-VCA IgG, as indicated by AI values greater 
than 1.5, was present in a small percentage of RRMS patients and controls (RRMS=6%, 
OIND=7%, NIND=2% for EBNA-1-specific AI; RRMS=2%, OIND=5%, NIND=1% for VCA-
specific AI), without any statistical differences among the groups.  
 
EBV-specific IgG OCB in RRMS patients  
EBV-specific IgG OCB were detected in 25/100 (25%) RRMS patients (Table 7). Four different 
profiles were recognized (“normal”; “local synthesis”; “mixed” and “mirror). Among these, “local 
synthesis” and “mixed” patterns indicated an intrathecal synthesis of anti-EBV IgG OCB, whereas 
“mirror” pattern revealed an EBV-specific systemic oligoclonal response. Twenty-one RRMS 
patients had “local synthesis”, 3 had “mixed” and 1 had “mirror” patterns. Two illustrative cases 
describing paired total and EBV-specific IgG OCB from RRMS patients are reported in Figure 8. 
RRMS patients with and without intrathecally synthesized EBV-specific IgG OCB did not differ for 
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disease duration and severity, clinical and MRI activity, and CSF and serum anti-EBNA-1 and anti-
VCA IgG concentrations, with the exception of anti-VCA IgG concentrations in serum which were 
greater in ASI negative than in ASI positive RRMS (Mann-Whitney: p<0.05).  
 
Table 7. Demographic and clinical features, and CSF and serum and intrathecal synthesis of anti-
EBNA-1 and anti-VCA IgG levels in 100 relapsing-remitting multiple sclerosis (RRMS) patients 
divided according to antigen-specific immunoblotting (ASI) findings. 
 
ASI positive 
RRMS (n=24) 
ASI negative 
RRMS (n=76) 
Sex: F/M 17/7 53/23 
Age, years: mean ± SD 36.7 ± 9.1 37.5 ± 11.1 
Disease duration, months: mean ± SD 28.7 ± 40.2 30.8 ± 48.5 
Disease severity, EDSS: mean ± SD 2.2 ± 1.5 2.0 ± 1.2 
CA MS: n/total (%) 20/24 (83.3%) 57/76 (75.0%) 
CA MS: n/total (%) 4/24 (16.7%) 19/76 (25.0%) 
Gd+ MS: n/total (%) 13/24 (54.2%) 24/76 (31.6%) 
Gd- MS: n/total (%) 11/24 (45.8%) 52/76 (68.4%) 
CSF anti-EBNA-1 IgG (AU): mean ± SD  193.0 ± 266.0 155.2 ± 232.1 
CSF anti-VCA IgG (AU): mean ± SD 41.6 ± 56.9 81.5 ± 243.4 
Serum anti-EBNA-1 IgG (AU): mean ± SD  126502 ± 205623 132114 ± 198699 
Serum anti-VCA IgG (AU): mean ± SD 21572 ± 24497 50122 ± 75151
a
 
EBNA-1 AI > 1.5: n/total (%) 3/21 (12.5%) 3/76 (4.0%) 
VCA AI > 1.5: n/total (%) 1/21 (4.2%) 1/76 (1.3%) 
ASI positive = presence of EBV-specific IgG oligoclonal bands; ASI negative = absence of EBV-
specific IgG oligoclonal bands; EDSS = Expanded disability status scale; CA = Clinically Active 
(presence of relapse at entry); CS = Clinically Stable (absence of relapse at entry); Gd+ = MRI 
appearance of gadolium enhancing lesions; Gd- = no MRI evidence of gadolium enhancing; SD = 
standard deviation. AI > 1.5 = Antibody Index abnormal values suggestive of EBV-specific 
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intrathecal synthesis; Serum anti-EBNA-1 IgG levels (Mann–Whitney): 
a
ASI negative vs. ASI 
positive (p < 0.05). 
 
Figure 8. Comparison between total (A) and EBV-specific (B) IgG OCB profiles obtained with 
isoelectric focusing and antigen-specific immunoblotting, respectively, in paired cerebrospinal fluid 
(CSF) and serum samples of two relapsing-remitting multiple sclerosis (RRMS) patients. 
Corresponding bands are indicated by arrows. Among RRMS patients with EBV-specific IgG OCB, 
CSF-restricted total IgG OCB were absent only in a RRMS patient with a “mirror” pattern. In the 
remaining 24 RRMS patients with an EBV-specific intrathecal oligoclonal IgG synthesis there was 
a little overlap between total and virus-specific IgG OCB unique-to-CSF due to their high 
individual variability. More precisely, EBV-specific numbered less (mean ± SD = 3.6 ± 1.9; range 
from 2 to 9) than total IgG OCB (mean ± SD = 9.9 ± 4.6; range from 2 to 20), and did not always 
correspond to them because of the presence of additional bands in antigen-specific immunolotting 
which were not visible in IEF.  
 
None of the patients with OIND and NIND showed OCB specifically directed against EBV, not 
even those with total IgG OCB (9 OIND and 2 NIND with “local synthesis”, 1 OIND and 1 NIND 
with “mixed”, 8 OIND and 7 NIND  with “mirror” and  3 OIND with “monoclonal” patterns).  
 
Affinity distributions of anti-EBNA-1 and anti-VCA IgG in RRMS patients and controls 
Affinity distributions of anti-EBNA-1 and anti-VCA IgG were quantitatively evaluated in CSF and 
serum from a representative subpopulation of 50 RRMS (34 female and 16 male, mean 
age=34.9±8.2) and 50 OIND (34 female and 16 male, mean age=35.5±8.8), 50 NIND patients (34 
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female and 16 male, mean age=36.1±8.3) with high titers of both these EBV-specific antibodies. 
All RRMS, OIND and NIND patients with AI abnormal values and all RRMS patients with EBV-
specific IgG OCB were included. CSF and serum Relative Affinity (RA) values obtained with 
increasing concentrations of NaSCN were significantly greater for anti-EBNA-1 IgG than for anti-
VCA IgG at the lowest concentration of NaSCN while, on the contrary, for anti-VCA IgG than for 
anti-EBNA-1 IgG at higher NaSCN concentration, whereas no differences were found at the highest 
concentration of NaSCN in all the three groups analyzed (Figure 9, Panels A, B, C, D, E and F).  
 
Figure 9. Relative affinity (RA) of anti-EBNA-1 IgG (white boxes) and of anti-VCA IgG (grey 
boxes) values obtained with increasing concentrations of sodium thiocyanate (NaSCN) in CSF and 
serum from 50 RRMS, 50 OIND and 50 NIND patients. CSF and serum RA1 values were higher 
for anti-EBNA-1 IgG than for anti-VCA IgG in RRMS (panels A and D; Mann-Whitney; 
p<0.0001), OIND (panels B and E; Mann-Whitney; p<0.0001) and NIND (panels C and F; Mann-
Whitney; p<0.0001). CSF RA2 values were more elevated for anti-VCA IgG than for anti-EBNA-1 
IgG in OIND (panel B; Mann-Whitney; p<0.01) and NIND (panel C; Mann-Whitney; p<0.05). 
Serum RA2 values were greater for anti-VCA IgG than for anti-EBNA-1 IgG in RRMS (panel D; 
Mann-Whitney; p<0.01), OIND (panel E; Mann-Whitney; p < 0.05) and NIND (panel F; Mann-
Whitney; p<0.01). CSF RA3 values were higher for anti-VCA IgG than for anti-EBNA-1 IgG in 
RRMS (panel A; Mann-Whitney; p<0.001) and OIND (panel B; Mann-Whitney; p<0.001). Serum 
RA3 values were more increased for anti-VCA IgG than for anti-EBNA-1 IgG in RRMS (panel D; 
Mann-Whitney; p<0.05), OIND (panel E; Mann-Whitney; p<0.0001) and NIND (panel F; Mann-
Whitney; p<0.001). The boundaries of the boxes represent the 25th–75th quartile. The line within 
the box indicates the median. The vertical lines above and below the box correspond to the highest 
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and lowest values, excluding outliers. MS: relapsing-remitting multiple sclerosis; OIND: other 
inflammatory neurological disorders; NIND: non-inflammatory neurological disorders; RA1: 
percentage of IgG removed by 1.25M NaSCN; RA2: percentage of IgG removed by 2.5M NaSCN; 
RA3: percentage of IgG removed by 5M NaSCN; RA4: percentage of IgG remaining after 
treatment with 5M NaSCN.  
 
 
As illustrated in Table 8, CSF high-affinity anti-EBNA-1 IgG, as indicated by RA4 value at 5M 
NaSCN > 2.5%, were significantly more frequent in RRMS (p<0.05) than in NIND, while CSF 
high-affinity anti-VCA IgG were statistically more represented in RRMS and OIND (p<0.05) than 
in NIND. On the other hand, serum high-affinity anti-VCA IgG were significantly more common in 
RRMS (p<0.01) than in NIND.  
 
Table 8. CSF and serum distributions of high-affinity anti-EBNA-1 and anti-VCA IgG in a 
subgroup of RRMS, OIND and NIND patients.   
 RRMS 
(n = 50) 
OIND 
(n = 50) 
NIND 
(n = 50) 
CSF anti-EBNA-1 IgG: AR4 > 2.5, n/total (%) 48/50 (96%)
a 
45/50 (90%) 40/50 (80%) 
CSF anti-VCA IgG: AR4 > 2.5, n/total (%) 48/50 (96%)
b 
47/50 (94%)
c 
40/50 (80%) 
serum anti-EBNA-1 IgG: AR4 > 2.5, n/total (%) 47/50 (94%) 47/50 (94%) 48/50 (96%) 
serum anti-VCA IgG: AR4 > 2.5, n/total (%) 44/50 (88%)
d 
40/50 (80%) 32/50 (64%) 
RRMS = relapsing-remitting multiple sclerosis; OIND = other inflammatory neurological disorders; 
NIND = non-inflammatory neurological disorders; AR4 = affinity ratio 4, percentage of IgG 
remaining after treatment with 5 M NaSCN. CSF anti-EBNA-1, AR4 > 2.5 (Chi-square with 
Bonferroni correction): 
a
RRMS vs. NIND (p<0.05); CSF anti-VCA, AR4 > 2.5 (Chi-square with 
Bonferroni correction): 
b
RRMS vs. NIND (p<0.05) and 
c
OIND vs. NIND (p<0.05); serum anti-
VCA: AR4 > 2.5 (Chi-square with Bonferroni correction): 
d
MS vs. NIND (p<0.01). 
 
No other statistical differences were found among the groups evaluated and between RRMS 
patients with and without clinical and MRI active disease. When we considered affinity ratio (AR), 
CSF for anti-EBNA-1 and anti-VCA IgG were statistically different among RRMS, OIND and 
NIND (Kruskal-Wallis: p<0.0001). More precisely, CSF AR values were significantly higher in 
RRMS and OIND than in NIND for anti-EBNA-1 and anti-VCA IgG  (p<0.0001) (Figure 10, 
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panels A and B), without any further statistical differences between RRMS and controls for anti-
EBNA-1 and anti-VCA IgG serum AR values (Figure 10, panels C and D).  
 
Figure 10. Affinity Ratio (AR) values of anti-EBNA-1 IgG and of anti-VCA IgG in CSF and serum 
from 50 RRMS, 50 OIND and 50 NIND patients. Anti-EBNA-1 IgG and anti-VCA IgG  CSF AR 
values were significantly higher in MS and OIND than in NIND (Mann-Whitney with Bonferroni 
correction; p<0.0001 in all cases) (Panels A and B), without any further statistical differences 
between MS and controls for anti-EBNA-1 IgG and anti-VCA IgG serum AR values (Panels C and 
D). Each point represents a single observation, excluding outliers. Horizontal bars indicate medians 
and error bars correspond to standard error. 
 
Affinity distributions of EBV-specific oligoclonal antibodies 
Affinity distributions of EBV-specific IgG OCB were qualitatively assessed in CSF from all 24 
RRMS patients with EBV-specific CSF-restricted oligoclonal IgG response. In all CSF samples 
analyzed, EBV-specific IgG OCB were found to have low affinity since they completely 
disappeared after treatment with the highest concentration (5M) of NaSCN. Particularly, in only 4 
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CSF samples EBV-specific IgG OCB persisted at a concentration of 2.5M NaSCN, whereas in the 
remaining 20 CSF specimens EBV-specific IgG OCB were lost after treatment with 1.25M NaSCN 
concentration.  Figure 11 depicts three explicative cases showing the effects on intensity of EBV-
specific OCB IgG of increasing concentrations of NaSCN in RRMS patients. 
 
Figure 11. Changes in intensity of EBV-specific IgG OCB (arrows) detected by Antigen-mediated 
immunoblots (AMI) specific for EBV performed with employment of different concentration of 
NaSCN. A) Untreated: 0M NaSCN  (saline buffer); B) 1.25 M NaSCN; C) 2.5 M NaSCN; D) 5 M 
NaSCN.  
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DISCUSSION (1) 
In this study, we investigated different aspects of CSF and serum EBV-specific humoral immune 
response in RRMS focusing on intrathecal production and affinity distributions of EBV-specific 
IgG. We here showed that concentrations of anti-EBNA-1 IgG were higher in RRMS and OIND 
than in NIND in CSF and in RRMS than in OIND and NIND in serum. Interestingly, an inverse 
correlation between serum levels of anti-EBNA-1 IgG and EDSS was observed in RRMS. On the 
contrary, CSF anti-VCA IgG levels were higher in OIND than in RRMS and NIND. No 
relationships were found between anti-EBNA-1 and anti-VCA IgG and clinical and MRI MS 
activity, and an intrathecal synthesis of anti-EBNA-1 and anti-VCA IgG were observed in a 
minority of RRMS patients and controls. These results confirm that, while serum levels of anti-
EBNA-1 IgG can be considered as a hallmark of MS (Santiago et al, 2010; Almohmeed et al, 2012) 
elevated CSF amounts of  anti-EBNA-1 IgG do not seem to be selectively associated with MS, but 
are shared by several inflammatory neurological conditions (Castellazzi et al, 2010). In accordance 
with our recent publication (Castellazzi et al, 2010), but in contrast with other previous studies 
(Farrell et al, 2009; Lünemann et al, 2010) our results do not support the value of serum titers of 
anti-EBNA-1 IgG as biomarker for MS disease activity and progression but indicate that an increase 
in disability may be linked to a decline in systemic humoral reaction to EBNA-1. In addition, our 
findings further pointed out the poor significance of CSF and serum levels of anti-VCA IgG, 
although serum concentrations of anti-VCA IgG were repeatedly related to MS (Santiago et al, 
2010; Almohmeed et al, 2012) and an association between them and MRI cortical atrophy was 
recently described (Zivadinov et al, 2009). On the other hand, the low rate of detection for an 
intrathecal release of anti-EBNA-1 and anti-VCA IgG documented in RRMS and controls was 
concordant with all (Pohl et al, 2010; Castellazzi et al, 2010; Jafari et al, 2010, Sargsyan et al, 2010; 
Villegas et al, 2011; Otto et al, 2011) but two (Jaquièry et al, 2010; Rand et al, 2000) prior 
investigations, providing additional evidence that EBV-specific intrathecally produced antibodies 
are innocent bystanders reflecting a polyspecific humoral reactivity directed against many different 
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pathogens not related to the cause of the disease and promoted by the overactive chronic immune 
stimulation associated with MS brain inflammation (Pohl et al, 2010; Otto et al, 2011) The 
divergences which emerged with previous studies (Rand et al, 2000; Farrell et al, 2009, Zivadinov 
et al, 2009; Lünemann et al, 2010; Jaquièry et al, 2010) may derive from differences in patient 
selection and determination techniques, highlighting, moreover,  the need for standardized 
protocols. The methodological issues could also explain the discrepancies found between our and 
some earlier investigations for CSF-restricted EBV-specific OCB which were recognized in  MS 
patients (Rand et al, 2000; Cepok et al, 2005b; Serafini et al, 2007; Franciotta et al, 2011; Virtanen 
et al, 2014). We exclusively detected EBV-specific OCB restricted to CSF in 24% RRMS patients 
suggesting that, as qualitative analysis is more sensitive than quantitative in the determination of an 
intrathecal IgG synthesis (Thompson, 2004) an EBV targeted intrathecal humoral immune response 
implying that an EBV persistent chronic brain infection may occur in a subset MS patients. 
However, our affinity qualitative studies demonstrated that CSF-restricted EBV-specific OCB had 
low affinity in all RRMS patients. These findings indicate that EBV-specific intrathecal oligoclonal 
high-affinity antibodies are absent in MS. Therefore, as the process of immune maturation 
promoted by an infection leads to a gradual increase in antibody affinity resulting in a strong 
production of high-affinity antibodies specifically directed against the causative pathogen (Luxton 
and Thompson, 1990) our observations collectively argue against the possibility that an EBV 
persistent brain chronic infection may exist in MS. This suggests that the widely accepted 
association between anti-EBNA-1 IgG and MS may not always correspond to causation (Virgin et 
al, 2009). Conversely, quantitative analysis based on RA4 value at 5M NaSCN > 2.5% and AR 
collectively demonstrated that CSF high-affinity anti-EBNA-1 and anti-VCA IgG were more 
frequent in RRMS and OIND than in NIND and equally represented in RRMS and OIND. In 
absence of an oligoclonal intrathecal production of high affinity antibodies, these results suggest the 
presence of an EBV-specific polyclonal humoral immune response operating in CSF compartment 
that is not limited to MS, but represents a common feature of inflammatory CNS disorders, which is 
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predominantly blood-derived, and, thus, likely reflects an antecedent EBV infection during puberty 
(Hangartner et al, 2006). In addition, this reaction may be in part induced by a polyclonal activation 
of memory B cells and long-lived plasma cells which predominate within the inflammatory brain 
microenvironment (Meinl et al, 2006). Intriguingly, we observed, in both RRMS and controls, the 
occurrence of higher affinity anti-EBV viral surface protein (VCA) antibodies in comparison with 
those specific for nuclear viral proteins released from dying cells (EBNA-1). These results prove 
that EBV acts as an intermittently cytopathic virus (Hangartner et al, 2006). In summary, this study 
has shown that, at intrathecal level, MS is generally marked by polyclonal high-affinity anti-EBV 
antibodies which passively transudate from serum. In a subset of patients (24%), there are 
additional EBV-specific oligoclonal low-affinity antibodies which are locally synthesized within the 
CNS. These data do not justify the hypothesis that EBV persistence leading to a productive 
infection in the brain can play a role in MS. Nevertheless, the presumed EBV persistent CNS 
infection may occur in a latent form that, unlike the chronic form, is characterized by an intermittent 
and not a continual antigen stimulation without a significant production of specific CSF and serum 
antibodies (Lipton et al, 2007). Thus, the possibility that EBV is a cofactor in the development and 
maintenance of the disease, sustaining the polyspecific intrathecal antibody synthesis typical of MS 
(Franciotta et al, 2008) cannot be completely excluded. In addition, in this study we did not explore 
other potential mechanisms which can trigger MS autoimmunity such as molecular mimicry 
consisting of a cross-reaction between EBV and CNS self-antigens (Lang et al, 2002), bystander 
damage due to a dysregulation of EBV infection within the brain (Serafini et al, 2007) and 
accumulation of EBV infected autoreactive B cells in the CNS related to a decrease in systemic 
CD8 T cell control of EBV infection (Lucas et al, 2011). Finally, our results do not exclude the 
hypothesis that a dysregulated EBV infection of B cells may play a role in MS autoimmunity 
(Pender, 2003; Pender, 2011). 
 
  
  52 
RESULTS (2) 
 
Serum levels of anti-EBNA-1 and anti-VCA IgG in TYSABRI®-treated RRMS patients 
Only for eleven patients was it possible to perform the analysis at each time point, on the contrary 
for nine patients the sample collection was not carried out at all the various time points. This could 
be the main bias of the study. However, we decided to analyse the samples all together at each time 
point. Detectable levels of anti-EBNA-1 IgG were present in 100% of analyzed samples. The 
distribution of data was verified for each time point by the Kolmogorov-Smirnov test. As shown in 
Table 9, mean levels of anti-EBNA-1 IgG had a normal distribution at all times with the exception 
of the twelfth month (T12, P value <0.05). Despite the increase in the mean levels from the ninth 
month of therapy, the statistical analysis of the data with the Kruskal-Wallis test did not reveal any 
significant differences between the concentrations analyzed. 
 
Tabel 9. Longitudinal fluctuations of anti-EBNA-1 IgG levels in 20 RRMS patients during 15 
months of TYSABRI® tretment. *p < 0.05; SD = standard deviation; AU = arbitrary units; KS = 
Kolmogorov-Smirnov; T0 = baseline; T3 = 3rd month; T6 = 6th month; T9 = 9th month; T12 = 
12th month; T15 = 15th month. 
 
Time point Serum anti-EBNA-1 IgG concentrations (AU)  KS normality test 
 mean ± SD Range  P value 
T0 (n=16) 28710 ± 15513 3424 – 58213  > 0.10 
T3 (n=19) 27479 ± 15022 2115 – 56053  > 0.10 
T6 (n=19) 28772 ± 15498 2965 – 64063  > 0.10 
T9 (n=19) 34909 ± 30986 1672 – 143774  0.0974 
T12 (n=20) 37735 ± 37214 2744 – 164574  0.0012* 
T15 (n=18) 37650 ± 26581 2184 – 101307  > 0.10 
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Detectable levels of anti-VCA IgG were present in all the samples tested. The distribution of 
antibody levels at every time point was verified by the Kolmogorov-Smirnov test (Table 10). 
Comparison of the mean concentrations obtained at every time point with the Kruskal-Wallis test 
did not reveal any significant differences. 
 
Tabel 10. Longitudinal fluctuations of anti-VCA IgG levels in 20 RRMS patients during 15 months 
of TYSABRI® tretment. *p < 0.05; SD = standard deviation; AU = arbitrary units; KS = 
Kolmogorov-Smirnov; T0 = baseline; T3 = 3rd month; T6 = 6th month; T9 = 9th month; T12 = 
12th month; T15 = 15th month. 
 
Time point Serum anti-VCA IgG concentrations (AU)  KS normality test 
 mean ± SD Range  P value 
T0 (n=16) 103019 ± 56996 14911 – 199402   > 0.10 
T3 (n=19) 97027 ± 54339 17730 – 203687   > 0.10 
T6 (n=19) 99606 ± 53866 19985 – 190493   > 0.10 
T9 (n=19) 119322 ± 74596 29345 – 343112  > 0.10 
T12 (n=20) 125215 ± 86778   8708 – 364044  > 0.10 
T15 (n=18) 139741 ± 75789 38082 – 286458  0.0414* 
 
 
Serum levels of anti-EBNA-1 and anti-VCA IgG in TYSABRI®-treated RRMS patients 
grouped into responders and nonresponders 
According to very stringent criteria (Fainardi et al, 2004), 15 RRMS patients who experienced 
complete disappearance of clinical attacks were classified as “responders”, while 5 RRMS patients 
having no cessation of relapses were indicated as “nonresponders”. Despite the low sample size, 
statistical analysis with Student’s t test showed no difference between responders and 
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nonresponders both for anti-EBNA-1 and anti-VCA IgG at each time point (Figure 12, panels A and 
B). 
 
 
Figure 12. Temporal fluctuations of anti-EBNA-1 and anti-VCA IgG in RRMS patients grouped 
according to therapy response. Panel A) Anti-EBNA-1 IgG: T0, Resp Vs NoResp (t test; p = 
0.1696); T3, Resp Vs NoResp (t test; p = 0.1738); T6, Resp Vs NoResp (t test; p = 0.2295); T9, 
Resp Vs NoResp (t test; p = 0.9077); T12, Resp Vs NoResp (t test; p = 0.7934); T15, Resp Vs 
NoResp (t test; p = 0.0999). Panel B) Anti-VCA IgG: T0: Resp Vs NoResp (t test; p = 0.6108); T3, 
Resp Vs NoResp (t test; p = 0.6328); T6, Resp Vs NoResp (t test; p = 0.3885); T9, Resp Vs NoResp 
(t test; p = 0.5397); T12, Resp Vs NoResp (t test; p = 0.2076); T15, Resp Vs NoResp (t test; p = 
0.2006). The boundaries of the boxes represent the 25th–75th quartile. The line within the box 
indicates the median. The vertical lines above and below the box correspond to the highest and 
lowest values, excluding outliers. Responders: patients who experienced complete disappearance of 
clinical attacks; Non-responders: patients having no cessation of relapses.  
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DISCUSSION (2) 
At the best of our knowledge, temporal fluctuations of serum levels of EBV-specific IgG in RRMS 
patients receiving TYSABRI® have never been investigated before. In recent decades, several 
studies have shown correlations between antibodies specific for certain antigens of EBV, in 
particular antigens EBNA-1 and VCA, and some clinical features of MS, such as onset, progression, 
activity and severity (Farrell et al, 2009; Lünemann et al, 2010; Ascherio and Munger, 2010; 
Almohmeed et al, 2013). For these reasons, these antibodies should be considered serological 
markers of the natural history of the disease, or “type 0 biomarkers” (Bielekova and Martin, 2004). 
However, our data seem to exclude the role of EBV-specific antibody response as a biomarker for 
the evaluation of therapeutic response, “type 1 biomarkers”, to TYSABRI®. In fact, during 15 
months of therapy, temporal fluctuations of EBV-specific antibodies were not affected by drug 
treatment. This lack of statistical significance was also confirmed by the comparison between 
patients who responded to treatment and patients who had, instead, relapses during the study period. 
This is in contrast with previous studies in which the levels of anti-EBNA-1 IgG correlated with 
disease activity (Farrell et al, 2009) and anti-VCA IgG correlated with the progression of the 
disease (Zivadinov et al, 2009). The main limitations of this study were certainly the low number of 
enrolled subjects and the fact that all serum samples were not available for some patients. Another 
limiting factor is the lack of samples collected at the time of relapse which could have provided 
better guidance on correlations with clinical activity. Taken together, these data argue against the 
use of EBV-specific antibody levels as biomarkers for monitoring therapeutic response to 
TYSABRI® in the course of relapsing-remitting multiple sclerosis. However, future studies are 
needed to verify the actual significance of anti-EBV antibodies in MS patients who are undergoing 
TYSABRI® therapy.  
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CONCLUSIONS 
In this study we deeply investigated the relationship between EBV and MS by evaluating the 
affinity distribution of the virus-specific antibodies at the time of diagnosis and the temporal 
fluctuations of these antibodies during disease modifying therapy. The main results are summarized 
as follow: 
a) multiple sclerosis is associated to elevated serum titers of anti-EBV antibodies, in particular 
of anti-EBNA-1 IgG, reflecting a past EBV infection; 
b) the occurrence of higher affinity anti-EBV viral surface protein (VCA) antibodies in 
comparison with those specific for nuclear viral proteins released from dying cells (EBNA-
1) is a shared condition in both MS and CNS inflammatory diseases, and confirms that EBV 
can act as an intermittently cytopathic virus; 
c) in a subset of MS patients (24%) an intrathecal synthesis of EBV-specific oligoclonal low-
affinity antibodies was observed, and these data do not justify the hypothesis that EBV 
persistence leads to a productive infection in the brain which can play a role in MS; 
d) the in-depth analysis of the virus-specific antibody response suggests that the widely 
accepted association between anti-EBNA-1 IgG and MS may not always correspond to 
causation; 
e) although serum titers of anti-EBNA-1 IgG are considered a biomarker for the natural history 
of MS, the study of the EBV-specific antibody response in patients treated with TYSABRI® 
seems to exclude the use of these antibodies as biomarkers of  therapeutic intervention. 
Taken together, our results do not argue against the hypothesis that a dysregulated EBV infection of 
B cells may play a role in MS pathogenesis. 
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